Slide We are in this together. WHO WE ARE Purposeful Ambition Taking on cancer requires grit and dedication. All of us at Mythic Therapeutics—leaders, employees, and advisers—are dedicated to applying our collective capabilities, experience, and creativity toward developing a new dimension of antibody-drug conjugates (ADC) to transform the lives of patients.

Our powerful FateControl™ technology dramatically increases the therapeutic potency of ADCs without increasing toxicity, resulting in smarter and safer medicines that can target an array of tumor targets.

Leadership

Brian Fiske

Brian Fiske, PhD

CHIEF SCIENTIFIC OFFICER AND CO-FOUNDER
Sandra Poole

Sandra Poole, MASc, P.Eng

CHIEF OPERATING OFFICER
Gilles Gallant

Gilles Gallant, BPharm, PhD, FOPQ

CHIEF DEVELOPMENT OFFICER
Ben Hutchins

Ben Hutchins, PhD

VICE PRESIDENT OF TECHNICAL OPERATIONS
Nimish Gera

Nimish Gera, PhD

VICE PRESIDENT OF BIOLOGICS
Tom Chittenden

Tom Chittenden, PhD

SENIOR VICE PRESIDENT, HEAD OF BIOLOGY

Scientific Advisory Board

Richard Gregory, PhD

Former EVP & CSO, ImmunoGen

Douglas Williams, PhD

President & CEO, Codiak BioSciences

Michael Vasconcelles, MD

CMO, Flatiron Heath

John Lambert, PhD

Former EVP & CSO, ImmunoGen

Scott Dylla, PhD

Former VP R&D, CSO, Abbvie Stemcentrx

Board of Directors

Bryan Roberts, PhD

Partner, Venrock

Peter Hecht, PhD

Co-Founder & CEO, Cyclerion

Josh Kopelman

Partner, First Round Capital

Brian Fiske, PhD

CSO

Together, let’s re-envision cancer therapy.